We are live on ! Find out more

Maze Therapeutics

MAZE

Market cap $1.75B

31.48 USD

-0.45

1.41%

At close Updated Oct 30, 4:00 PM EDT

Pre-market

After hours

30.59

-0.89

2.83%

1 day

-1.41%

5 days

1.78%

1 month

15.82%

3 months

13.93%

6 months

18.43%

Year to date

-20.84%

1 year

-5.24%

5 years

97.37%

10 years

97.37%

About: Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.

Employees: 141

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 50%

Neutral 41.7%

Negative 8.3%

Zacks Investment Research

What Makes Maze Therapeutics, Inc. (MAZE) a New Buy Stock

Maze Therapeutics, Inc. (MAZE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Maze Therapeutics, Inc. (MAZE) a New Buy Stock

Zacks Investment Research

How Much Upside is Left in Maze Therapeutics, Inc. (MAZE)? Wall Street Analysts Think 123.39%

The average of price targets set by Wall Street analysts indicates a potential upside of 123.4% in Maze Therapeutics, Inc. (MAZE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

How Much Upside is Left in Maze Therapeutics, Inc. (MAZE)? Wall Street Analysts Think 123.39%

Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026

Oral presentation will highlight previously reported Phase 2 HORIZON data for MZE829 in patients with APOL1-mediated kidney disease Two poster presentations will highlight preclinical research supporting the therapeutic potential of SLC6A19 inhibition in chronic kidney disease SOUTH SAN FRANCISCO, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that the company will present data supporting its lead programs, MZE829 and MZE782, during the American Society of Nephrology (ASN) Kidney Week, being held October 21–25, 2026, in Denver, Colorado.

Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026

3 Small-Cap Stocks With Catalysts That Could Put Them in the Spotlight

Small-cap companies are accustomed to living in the shadow of mega-cap tech firms, but there are signs that the market backdrop could be changing for some of these companies. Investors have been looking beyond the Magnificent Seven for growth opportunities, and smaller companies with improving fundamentals, unique business models, or other noteworthy catalysts may finally have an opportunity to win investor attention.

3 Small-Cap Stocks With Catalysts That Could Put Them in the Spotlight

Investors Business Daily

The Surprise That Sent Vertex — And Its Chief Rival — Soaring

Vertex stock popped Tuesday — while shares of rival Maze Therapeutics skyrocketed — on a surprise expansion for their kidney disease drugs.

The Surprise That Sent Vertex — And Its Chief Rival — Soaring

Vertex's Kidney Drug Success Sparks a 22% Surge for This Rival Biotech

Maze Therapeutics stock jumped after Vertex Pharmaceuticals reported positive results for inaxaplin, boosting confidence in a rival treatment from Maze.

Vertex's Kidney Drug Success Sparks a 22% Surge for This Rival Biotech

The Motley Fool

Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000

Chief Medical Officer Harold Bernstein sold 9,705 shares for ~$255,000 on September 4, 2026. The transaction involved shares equal to 100% of the insider's directly held common stock before the filing.

Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000

Maze Therapeutics, Inc. (MAZE) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Maze Therapeutics, Inc. (MAZE) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Maze Therapeutics, Inc. (MAZE) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Maze Therapeutics to Participate in Three Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that company management will participate in three upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference; fireside chat on Wednesday, September 9, 2026, at 9:30 a.m.

Maze Therapeutics to Participate in Three Upcoming Investor Conferences

Maze Therapeutics: Intriguing Kidney Disease Assets Put This On The Watchlist

Maze Therapeutics, Inc. has advanced two lead precision medicine programs, MZE782 for PKU and MZE829 for APOL1-mediated kidney disease, with significant clinical progress. MZE782 demonstrated a best-in-class pharmacodynamic profile in Phase 1, supporting a transformative potential for PKU management; Phase 2 is set for mid-2026. MZE829 achieved strong uACR reductions in early Phase 2 data for AMKD, but faces competition from Vertex's inaxaplin; pivotal trials are planned for 1H 2027.

Maze Therapeutics: Intriguing Kidney Disease Assets Put This On The Watchlist

See News Rankings

Price charts implemented using Lightweight Charts™